Source: Eur Respir J 2003; 22: 161-172
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Saaresranta T., Polo O.. Sleep-disordered breathing and hormones. Eur Respir J 2003; 22: 161-172

Member's Comments

No comment yet.

Related content which might interest you: Ventilatory support and pharmacological treatment of patients with central apnoea or hypoventilation during sleep Source: Eur Respir Rev 2007; 16: 115-124 Year: 2007 Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients? Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Treatment of obstructive sleep-disordered breathing with positive airway pressure systems Source: Eur Respir Rev 2007; 16: 125-131 Year: 2007 CPAP and measures of cardiovascular risk in males with OSAS Source: Eur Respir J 2008; 32: 1488-1496 Year: 2008 Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation Source: Eur Respir J 2009; 33: 1068-1076 Year: 2009 Treatment options for central sleep apnea (including auto-CPAP) Source: Annual Congress 2005 - Central sleep apnoea Year: 2005 Obstructive sleep apnea Source: Respipedia Article Year: 2017 Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex Source: Eur Respir J 2003; 21: 241-247 Year: 2003 Residual sleep-disordered breathing during autotitrating continuous positive airway pressure therapy Source: Eur Respir J 2012; 39: 1391-1397 Year: 2012 Treatment with CPAP reduces mortality in patients with obstructive sleep apnoea syndrome within less than 3 years Source: Annual Congress 2006 - Therapeutic effects in obstructive sleep apnoea Year: 2006 The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients Source: Eur Respir J 2004; 23: 255-262 Year: 2004 Sleep, sleep-disordered breathing and metabolic consequences Source: Eur Respir J 2009; 34: 243-260 Year: 2009 Sleep apnoea and systemic hypertension Source: Eur Respir Mon 2010; 50: 150-173 Year: 2010 Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2003; 22: 251-257 Year: 2003 Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients Source: Eur Respir J 2009; 34: 694 Year: 2009 Treatment of obstructive sleep apnoea with nasal continuous positive airway pressure in stroke Source: Eur Respir J 2001; 18: 623-629 Year: 2001 Factors influencing the level of efficient pressure of continuous positive airway pressure (CPAP) in the treatment of obstructive sleep apnea (OSAS) Source: International Congress 2016 – Technical aspects, compliance, and adherence to positive airway pressure in sleep apnoea Year: 2016 Continuous positive airway pressure treatment in patients with OSA Source: Eur Respir Mon 2010; 50: 244-266 Year: 2010